Language:

Amyotrophic lateral sclerosis

The Lancet (British edition), 2022-10, Vol.400 (10360), p.1363-1380 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01272-7 ;PMID: 36116464

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Amyotrophic lateral sclerosis
Author: Feldman, Eva L ; Goutman, Stephen A ; Petri, Susanne ; Mazzini, Letizia ; Savelieff, Masha G ; Shaw, Pamela J ; Sobue, Gen
Subjects: Age ; Amyotrophic lateral sclerosis ; Amyotrophic Lateral Sclerosis - diagnosis ; Amyotrophic Lateral Sclerosis - genetics ; Amyotrophic Lateral Sclerosis - therapy ; Apathy ; Biomarkers ; Clinical trials ; Cognition & reasoning ; Dementia ; Diagnosis ; Disease ; Dysarthria ; Dysphagia ; Executive function ; Forecasting ; Genetics ; Health risk assessment ; Health risks ; Heterogeneity ; Humans ; Life expectancy ; Medical prognosis ; Medical referrals ; Neurodegenerative Diseases ; Patients ; Population ; Prediction models ; Prognosis ; Womens health
Is Part Of: The Lancet (British edition), 2022-10, Vol.400 (10360), p.1363-1380
Description: Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive research, current management of amyotrophic lateral sclerosis remains suboptimal from diagnosis to prognosis. Recognition of the phenotypic heterogeneity of amyotrophic lateral sclerosis, global CNS dysfunction, genetic architecture, and development of novel diagnostic criteria is clarifying the spectrum of clinical presentation and facilitating diagnosis. Insights into the pathophysiology of amyotrophic lateral sclerosis, identification of disease biomarkers and modifiable risks, along with new predictive models, scales, and scoring systems, and a clinical trial pipeline of mechanism-based therapies, are changing the prognostic landscape. Although most recent advances have yet to translate into patient benefit, the idea of amyotrophic lateral sclerosis as a complex syndrome is already having tangible effects in the clinic. This Seminar will outline these insights and discuss the status of the management of amyotrophic lateral sclerosis for the general neurologist, along with future prospects that could improve care and outcomes for patients with amyotrophic lateral sclerosis.
Publisher: England: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(22)01272-7
PMID: 36116464
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Amyotrophic lateral sclerosis

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01272-7 ;PMID: 36116464

Searching Remote Databases, Please Wait